For example, the twofold elevated risk for CRC associated with a CHEK2 mutation prompted a recommendation for enhanced surveillance with colonoscopy every 5 years beginning at age 40, in addition to the recommendation for annual breast MRI (75, 110). This evidence concerns the gene CHEK2 and colorectal carcinoma.